Five things for pharma marketers to know: Friday, March 31, 2017

Share this content:



1. A federal judge told Novartis to turn over documents with information about nearly 80,000 speaking events and dinners during which doctors were reportedly encouraged to prescribe its drugs. A whistleblower lawsuit alleges that the drugmaker paid bribes to increase prescriptions. (Stat)

2. Two drugmakers recently launched new drugs using the same strategy: setting lower-than-expected prices  at launch. Sanofi and Regeneron's Dupixent, a treatment for atopic dermatitis, costs $37,000 a year, much cheaper than the $50,000 a year charged by other companies marketing therapies that treat the same disease. (Bloomberg)

3. An accelerator invested $48 million in research projects to develop antibiotics that treat drug-resistant bacteria. About $24 million of that funding will go to 11 drugmakers. (WaPo)

4. Emma Walmsley, GlaxoSmithKline's new CEO, is set to assume leadership of the company this week. Her relative lack of pharmaceutical experience has been met with concern among investors. (WSJ)

5. ICYMI: PhRMA has been buying ads on TV shows that President Trump watches. The lobbying group has already spent $8.6 million on broadcast television and cable ads in 2017. (Bloomberg)

Share this content:
Scroll down to see the next article